Neuro Trials

Specific cardiogenic ischaemic cerebrovascular diseases (e.g. combined with atrial fibrillation, heart valve prosthesis, atrial myxoma, endocarditis, etc.)
 

Other ischaemic cerebrovascular diseases with specific causes (e.g. aortic dissection, vasculitis, vascular malformation, etc.)
 

Non-cerebral vascular disease (e.g. intracranial tumours, multiple sclerosis)
 

Cerebral infarction of large area (infarct size greater than half the single lobe area)
 

CT indicating haemorrhagic transformation of cerebral infarction before randomization
 

Pre-existing contraindication to clopidogrel, aspirin or statin drugs.

MRS > 2 before onset
 

Use of intravenous or arterial thrombolysis intravascular therapy or bridge therapy after onset.
 

Use of defibrinating therapy e.g. snake venom, defibrase, lumbrokinase, etc., use of anticoagulant therapy e.g argatroban, or use of antiplatelet therapy except clopidogrel and aspirin, such as tirofiban, ticagrelor, ozagrel, etc. after onset.
 

Creatine Kinase ≥5 times upper limit of normal value after onset.
 

Use of drugs affecting metabolism of statins such as immune-suppressive drugs, antifungal agents, or fibrates drugs within 14 days before randomisation.
 

Severe hepatic or renal insufficiency.
 

Usage of dual antiplatelet therapy with aspirin plus clopidogrel within 14 days before randomisation. (patients who received dual antiplatelet therapy [aspirin combined with clopidogrel] but did not use clopidogrel with loading dose after onset were excluded).
 

Use of Intensive statin therapy within 14 days before randomisation (atorvastatin ≥40mg/d or rosuvastatin ≥ 20mg/d).
 

Pre-existing intracranial haemorrhage.
 

GI bleeding or major surgery within 90 days before randomisation.
 

Pre-existing extracranial angioplasty or vascular surgery.
 

Anticipated requirement for long-term non-study antiplatelet drugs, or non-steroid anti-inflammatory drugs.
 

Experimental drugs need to stop due to angioplasty or vascular surgery, which was planned or likely to perform within 90 days after randomisation.
 

Patients with severe disease expected to live <90 days.
 

Pregnant or childbearing-age women who have no effective contraceptives or positive pregnancy test records.
 

Patients undergoing experimental drugs or device tests.
 

Unable to finish follow-up of 90 days.